DE10152306A1 - 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften - Google Patents

2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften

Info

Publication number
DE10152306A1
DE10152306A1 DE10152306A DE10152306A DE10152306A1 DE 10152306 A1 DE10152306 A1 DE 10152306A1 DE 10152306 A DE10152306 A DE 10152306A DE 10152306 A DE10152306 A DE 10152306A DE 10152306 A1 DE10152306 A1 DE 10152306A1
Authority
DE
Germany
Prior art keywords
alkyl
branched
straight
chain
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10152306A
Other languages
German (de)
English (en)
Other versions
DE10152306A8 (de
Inventor
Thomas Beckers
Siavosh Mahboobi
Herwig Pongratz
Markus Frieser
Harald Hufsky
Joerg Hockemeyer
Udo Vanhoefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Priority to DE10152306A priority Critical patent/DE10152306A1/de
Priority to JP2003540143A priority patent/JP2005516895A/ja
Priority to EP02802302A priority patent/EP1442015A1/de
Priority to PCT/EP2002/011883 priority patent/WO2003037861A1/de
Publication of DE10152306A1 publication Critical patent/DE10152306A1/de
Publication of DE10152306A8 publication Critical patent/DE10152306A8/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
DE10152306A 2001-10-26 2001-10-26 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften Withdrawn DE10152306A1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE10152306A DE10152306A1 (de) 2001-10-26 2001-10-26 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
JP2003540143A JP2005516895A (ja) 2001-10-26 2002-10-24 腫瘍の治療のための２−アシルインドールの使用
EP02802302A EP1442015A1 (de) 2001-10-26 2002-10-24 VERWENDUNG VON 2−ACYLINDOLEN ZUR BEHANDLUNG VON TUMOREN
PCT/EP2002/011883 WO2003037861A1 (de) 2001-10-26 2002-10-24 Verwendung von 2-acylindolen zur behandlung von tumoren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152306A DE10152306A1 (de) 2001-10-26 2001-10-26 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften

Publications (2)

Publication Number Publication Date
DE10152306A1 true DE10152306A1 (de) 2003-07-24
DE10152306A8 DE10152306A8 (de) 2004-07-08

Family

ID=7703459

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10152306A Withdrawn DE10152306A1 (de) 2001-10-26 2001-10-26 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften

Country Status (4)

Country Link
EP (1) EP1442015A1 (ja)
JP (1) JP2005516895A (ja)
DE (1) DE10152306A1 (ja)
WO (1) WO2003037861A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
US7608627B2 (en) * 2004-04-05 2009-10-27 Takeda Pharmaceutical Company Limited 6-azaindole compound
KR20070034049A (ko) 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
DE102009049211A1 (de) * 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2013112878A1 (en) * 2012-01-26 2013-08-01 The Penn State Research Foundation Mcl-1 modulating compositions
WO2014164708A1 (en) * 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
WO2016114816A1 (en) * 2015-01-18 2016-07-21 Sri International MAP4K4 (HGK) Inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
GB1472342A (en) * 1974-01-25 1977-05-04 Ciba Geigy Ag Derivatives of 2-2-pyridylcarbonyl-indole
GB2283745A (en) * 1993-11-12 1995-05-17 Merck Frosst Canada Inc Pharmaceutically active N-acylindoles
WO1999005104A1 (en) * 1997-07-23 1999-02-04 Pfizer Pharmaceuticals Inc. Indole compounds as cox-2 inhibitors
WO2001082909A2 (de) * 2000-04-28 2001-11-08 Baxter Healthcare Sa 2-acyl-indolderivate und deren verwendung als antitumormittel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
GB1472342A (en) * 1974-01-25 1977-05-04 Ciba Geigy Ag Derivatives of 2-2-pyridylcarbonyl-indole
GB2283745A (en) * 1993-11-12 1995-05-17 Merck Frosst Canada Inc Pharmaceutically active N-acylindoles
WO1999005104A1 (en) * 1997-07-23 1999-02-04 Pfizer Pharmaceuticals Inc. Indole compounds as cox-2 inhibitors
WO2001082909A2 (de) * 2000-04-28 2001-11-08 Baxter Healthcare Sa 2-acyl-indolderivate und deren verwendung als antitumormittel

Also Published As

Publication number Publication date
EP1442015A1 (de) 2004-08-04
JP2005516895A (ja) 2005-06-09
WO2003037861A1 (de) 2003-05-08
DE10152306A8 (de) 2004-07-08

Similar Documents

Publication Publication Date Title
EP1276720B1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
CN109820853B (zh) 取代的杂环化合物在制备治疗癌症药物中的用途
CN106536480B (zh) 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法
EP3386979B1 (de) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
AU2011237642B2 (en) Antimetastatic compounds
WO2016155545A1 (zh) 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
DE10152306A1 (de) 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
EP2616453A2 (en) Antimetastatic compounds
WO2016210247A1 (en) New methods of use for an anti-diarrhea agent
EP2714031A1 (en) A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck
RU2652992C2 (ru) Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения
JP6239103B2 (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
US20160214940A1 (en) Negative allosteric modulators of metabotropic glutamate receptor 2
WO2020028392A1 (en) Niclosamide analogues and therapeutic use thereof
KR101643306B1 (ko) 신규한 퀸옥살린 유도체 및 이의 용도
DE10102629A1 (de) 2-Acyl-indolderivate und deren Verwendung als Antitumormittel
DE10020852A1 (de) 2-Acryl-indolderivate und deren Verwendung als Antitumormittel
WO2003020731A1 (de) Cyclische indol-und heteroindolderviate, deren herstellung und verwendung als arzneimittel
CN114853746A (zh) 甲酰胺类化合物、其制备方法及其在医药上的应用
TW200803837A (en) Prophylactic or therapeutic agent for irritable bowel syndrome
EP1423393A1 (de) Anellierte indol- und heteroindolderivate, deren herstellung und verwendung als antitumormittel
WO2008040547A1 (de) Substituierte indeno[1,2-b]indolderivate als neue hemmstoffe der protein kinase ck2 und ihre verwendung als tumortherapeutika, cytostatika und diagnostika

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8196 Reprint of faulty title page (publication) german patentblatt: part 1a6
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8127 New person/name/address of the applicant

Owner name: BAXTER HEALTHCARE S.A., WALLISELLEN, CH

8128 New person/name/address of the agent

Representative=s name: BACHMANN, J., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW.,

8128 New person/name/address of the agent

Representative=s name: FREISE, B., RECHTSANW., 85716 UNTERSCHLEISSHEIM

8139 Disposal/non-payment of the annual fee